All In Biotech

Drug Trial Radar · NCT06603077

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa (LOTUS)

Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 253 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

253

Actual

Start

Sep 16, 2024

Primary completion

Feb 23, 2026

Study completion Mar 17, 2026

Sponsor

Lead sponsor
Avalo Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).

Conditions

  • Hidradenitis Suppurativa

Interventions

  • AVTX-009 Regimen 1Drug

    AVTX-009 will be administered as a subcutaneous injection every 4 weeks.

  • AVTX-009 Regimen 2Drug

    AVTX-009 will be administered as a subcutaneous injection every 2 weeks.

  • PlaceboDrug

    Matching placebo will be administered as a subcutaneous injection every 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)Time frame: At Week 16

Locations

89 sites in 13 countries. Site status is shown where the registry gives one.

  • Clinical Site 1022

    Scottsdale, Arizona

  • Clinical Site 1037

    Scottsdale, Arizona

  • Clinical Site 1026

    Tucson, Arizona

  • Clinical Site 1032

    Northridge, California

  • Clinical Site 1019

    Pomona, California

  • Clinical Site 1009

    Sacramento, California

  • Clinical Site 1034

    Santa Monica, California

  • Clinical Site 1011

    Washington D.C., District of Columbia

  • Clinical Site 1029

    Boca Raton, Florida

  • Clinical Site 1002

    Coral Gables, Florida

  • Clinical Site 1015

    Maitland, Florida

  • Clinical Site 1027

    North Miami Beach, Florida

  • Clinical Site 1013

    Tampa, Florida

  • Clinical Site 1008

    Savannah, Georgia

  • Clinical Site 1014

    Chicago, Illinois

  • Clinical Site 1028

    West Lafayette, Indiana

  • Clinical Site 1031

    Bowling Green, Kentucky

  • Clinical Site 1024

    Murray, Kentucky

  • Clinical Site 1042

    Boston, Massachusetts

  • Clinical Site 1001

    Boston, Massachusetts

  • Clinical Site 1030

    Detroit, Michigan

  • Clinical Site 1007

    Fort Gratiot, Michigan

  • Clinical Site 1041

    Oakland, Michigan

  • Clinical Site 1003

    Portsmouth, New Hampshire

  • Clinical Site 1036

    Brooklyn, New York

  • Clinical Site 1016

    New York, New York

  • Clinical Site 1023

    The Bronx, New York

  • Clinical Site 1020

    Cincinnati, Ohio

  • Clinical Site 1010

    Cleveland, Ohio

  • Clinical Site 1017

    Dublin, Ohio

  • Clinical Site 1004

    Philadelphia, Pennsylvania

  • Clinical Site 1035

    Pittsburgh, Pennsylvania

  • Clinical Site 1018

    Johnston, Rhode Island

  • Clinical Site 1025

    Providence, Rhode Island

  • Clinical Site 1005

    Greenville, South Carolina

  • Clinical Site 1012

    Arlington, Texas

  • Clinical Site 1203

    Darlinghurst, New South Wales, Australia

  • Clinical Site 1201

    Westmead, New South Wales, Australia

  • Clinical Site 1204

    Woolloongabba, Queensland, Australia

  • Clinical Site 1202

    Carlton, Victoria, Australia

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.